The Phase 2 N01 Program is a CTEP-CIP collaboration includes 7 contractors, most of whom consist of multi-institutional consortia, and includes a total of 22 NCI-designated Cancer Centers. These sites carry out early clinical trials with CTEP and CIP-held IND agents, with an emphasis on phase 2 trials, but including phase 1 trials as well. These trials include the evaluation of novel imaging agents and methods to enhance the evaluation of novel therapeutics.
The QIN Imaging Network is designed to promote research and development of quantitative imaging methods for the measurement of tumor response to therapies in clinical trial settings, with the overall goal of facilitating clinical decision making.
Cooperative agreement (U54) awards to establish Specialized Research Resource Centers that will participate as members of a network of inter-disciplinary, inter-institutional research teams for the purpose of supporting translational research in optical imaging and/or spectroscopy in vivo, with an emphasis on multiple modalities.
Resource grants that support shared imaging research resources to be used by cancer investigators and research related to small animal imaging technology.
ICMIC grants facilitate interaction among scientists from a variety of fields to conduct multidisciplinary research on cellular and molecular imaging related to cancer. Pre-ICMIC planning grants have provided time and funds for investigators and institutions to prepare themselves, organizationally and scientifically, to establish ICMICs.
DCIDE is no longer taking applications, as of August 2009. Imaging drug development resources should be requested through the new NExT/CBC program which has its own application and review process. See NCI Experimental Therapeutics Program (NExT). There are 4 review dates per year, instead of the previous DCIDE submission and review process.
Council brings together representatives of the Federal Government and technology developers to expedite the process of bringing new products to market.